Detalhe da pesquisa
1.
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
N Engl J Med
; 384(25): 2394-2405, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34081848
2.
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41.
Breast Cancer Res Treat
; 199(2): 243-252, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36944848
3.
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
N Engl J Med
; 380(25): 2395-2405, 2019 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31157962
4.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
N Engl J Med
; 380(7): 617-628, 2019 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30516102
5.
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer.
Breast Cancer Res Treat
; 192(1): 153-161, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35112166
6.
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Breast Cancer Res Treat
; 193(3): 555-564, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35230585
7.
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
N Engl J Med
; 379(2): 111-121, 2018 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29860917
8.
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
N Engl J Med
; 379(2): 122-137, 2018 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29863451
9.
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer.
Cancer
; 126(13): 3132-3139, 2020 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32286687
10.
Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19).
Rev Cardiovasc Med
; 21(4): 517-530, 2020 12 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33387997
11.
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(1): 88-99, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30509771
12.
Adjuvant Olaparib in BRCA-Mutated Breast Cancer. Reply.
N Engl J Med
; 385(15): 1440, 2021 10 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34614338
13.
Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination.
Breast Cancer Res Treat
; 178(2): 389-399, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31428908
14.
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Lancet Oncol
; 19(4): 497-509, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29501363
15.
Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Oncologist
; 23(4): 481-488, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29330212
16.
Adjuvant ovarian suppression in premenopausal breast cancer.
N Engl J Med
; 372(5): 436-46, 2015 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-25495490
17.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
N Engl J Med
; 373(21): 2005-14, 2015 Nov 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26412349
18.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
N Engl J Med
; 371(2): 107-18, 2014 Jul 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24881463
19.
Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Breast Cancer Res Treat
; 193(3): 565, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35507135
20.
Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial.
Ann Surg Oncol
; 24(2): 398-406, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27663567